Adicet Bio (ACET) Return on Capital Employed (2018 - 2026)
Adicet Bio (ACET) posted quarterly Return on Capital Employed of 70.0% for Q1 2026, down 311.0% year-over-year from 33.18% in Q1 2025, and up 16.95% quarter-over-quarter from 84.28% in Q4 2025.
Adicet Bio (ACET) Return on Capital Employed (2018 - 2026) Analysis & Trends
Adicet Bio's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 70.0% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 311.0% year-over-year to 70.0%; the TTM figure through Mar 2026 stood at 70.0% (down 311.0% YoY), while the FY2025 annual figure was 66.09%, down 44.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 70.0%, up from 84.28% in the prior quarter.
- The five-year high for Return on Capital Employed was 10.74% in Q1 2022, with the low at 91.1% in Q3 2025.
- The 5-year median for Return on Capital Employed is 59.72% (2024), against an average of 53.69%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 1675 bps in 2022, then sank 5317 bps in 2023.
- Adicet Bio's Return on Capital Employed stood at 22.48% in 2022, then sank by 237 bps to 75.65% in 2023, then rose by 21 bps to 59.72% in 2024, then tumbled by 41 bps to 84.28% in 2025, then rose by 17 bps to 70.0% in 2026.
- Business Quant data shows ACET's Return on Capital Employed at 70.0% in Q1 2026, 84.28% in Q4 2025, and 91.1% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - | -73.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.67% |
| Mar 31, 2026 | -70.00% |
| Dec 31, 2025 | -84.28% |
| Sep 30, 2025 | -91.10% |
| Jun 30, 2025 | -78.84% |
| Mar 31, 2025 | -66.89% |
| Dec 31, 2024 | -59.72% |
| Sep 30, 2024 | -53.96% |
| Jun 30, 2024 | -56.09% |
| Mar 31, 2024 | -64.27% |
| Dec 31, 2023 | -75.65% |
| Sep 30, 2023 | -64.51% |
| Jun 30, 2023 | -45.06% |
| Mar 31, 2023 | -36.89% |
| Dec 31, 2022 | -22.48% |
| Sep 30, 2022 | -17.40% |
| Jun 30, 2022 | -14.82% |
| Mar 31, 2022 | -10.74% |
| Dec 31, 2021 | -21.80% |
| Sep 30, 2021 | -22.74% |